Korea Republic Of

Yuhan Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CPhI Japan 2021

Participation Not Confirmed

Update your events

Yuhan’s Lung Cancer Treatment Lazertinib Wins Approval

Lead Product(s): Lazertinib

Therapeutic Area: Oncology Product Name: Leclaza

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 18, 2021

Details:

The Ministry of Food and Drug Safety announced its approval for the third-generation non-small cell lung cancer treatment, Leclaza. Leclaza is a swallowable tablet that can be taken at a fixed time every day, regardless of meals.

Samsung Bioepis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CPhI Japan 2021

Participation Not Confirmed

Update your events

Samsung Bioepis Unveils Clinical Follow-Up Results of 'Abincio'

Lead Product(s): Bevacizumab

Therapeutic Area: Oncology Product Name: Aybintio

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 15, 2020

Details:

The Incheon, Republic of Korea–based company said the study results supported preexisting evidence in support of equivalence between Aybintio and reference bevacizumab in patients with metastatic or recurrent nonsquamous non–small cell lung cancer.

Samsung Bioepis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CPhI Japan 2021

Participation Not Confirmed

Update your events

Samsung Bioepis Launches Ontruzant in Brazil

Lead Product(s): Trastuzumab

Therapeutic Area: Oncology Product Name: Ontruzant

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 10, 2020

Details:

ONTRUZANT® (trastuzumab) is Samsung Bioepis’ first oncology treatment and second product to be launched in Brazil followed by BRENZYS™, both in partnership with Bio-Manguinhos/Fiocruzi and Bionovis.